This is a preview of subscription content, log in via an institution to check access.
Reference
Shi Y, et al. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Advances in Therapy : 4 Jan 2020. Available from: URL: http://doi.org/10.1007/s12325-019-01214-y
Rights and permissions
About this article
Cite this article
Panitumumab + FOLFIRI for metastatic CRC: benefits at a cost. PharmacoEcon Outcomes News 845, 22 (2020). https://doi.org/10.1007/s40274-020-6525-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6525-y